Gaetano Scuderi, MD
CEO & Founder
Dr. Scuderi is the founder and president of Cytonics Corporation. Dr. Scuderi is a fellowship-trained spine surgeon and has practiced medicine since 1993. He has also recently worked as a Clinical Assistant Professor in the Department of Orthopedic Surgery of Stanford University. He graduated medical school from State University of New York at Buffalo, N.Y. and completed his Residency at University of Miami School of Medicine. He is fellowship trained in spine surgery fron UCSD. Dr. Scuderi has published over 45 scientific articles and has lectured world wide. Dr. Scuderi currently practices orthopedic surgery in Jupiter, FL.
Mr. Bose has over 10 years’ experience in biotechnology research development and investment banking. Based on his background in biomedical engineering and experience in the capital markets, Mr. Bose was recently appointed President of Cytonics. His primary responsibilities include coordinating capital raising efforts, initiating clinical trials for two lead drug candidates, filing and maintaining patent protection of intellectual property, and identifying strategic buyers and out-licensing opportunities for the company.
Mr. Bose began his R&D career at the University of Virginia where he developed a novel assay to measure phosphatase activity in the context of cancer biology. He continued his graduate studies in protein engineering at Johns Hopkins University, where he elucidated cell signaling pathways dysregulated in blood cancers. He went on to pursue a career in biotechnology investment banking at a number of boutique banks in Palm Beach County, Florida. He holds a B.S. in Biomedical Engineering from the University of Virginia and a M.S. in Biomedical Engineering from Johns Hopkins University.
Lewis Hanna, PhD
Vice President Research and Development
Dr. Hanna has served as our Vice President of Research and Development since February 2008. Dr. Hanna has over 28 years of research experience in pharmaceutical and biotechnology companies, focused on the structure and function of proteins including extensive experience working with therapeutic protein folding, purification, formulation, large-scale production, quality, and the regulatory requirements to obtain FDA new drug approval. Until 2004, Dr. Hanna was the Director of Process Development at Alexion Pharmaceutical, and prior to that was a Group Leader at Bristol-Myers Squibb Pharmaceutical Research Institute. For seven years, he was also a Principal Research Scientist at R.W. Johnson Pharmaceutical Research Institute. Dr. Hanna received his BS degree from Cairo University, received his PhD from City University of New York, and completed a post-doctoral fellowship at Cornell University.
Robert Bowser, PhD
Chief Scientific Officer
Dr. Robert Bowser is an internationally-recognized leader in ALS research. He has contributed to pioneering efforts to discover and validate biomarkers for ALS. These biomarkers can be useful as diagnostic indicators of disease, predictors of disease progression, and also in determining the effectiveness of drugs in clinical trials. Dr. Bowser has extensive experience in the translation of basic science discoveries to the clinic to impact patient care.